Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol
Michele Reni, Federica Iannelli, Mercedes Rodríguez Garrote, Francesca Foschini, Claudia Fuchs, Alfredo Budillon, Maria Serena Roca, Elena Di Gennaro, Giampaolo Tortora, Laura García‐Bermejo, Michele Stanislaw Milella, Christine Kubiak, Lucrezia Silvestro, Alessandra Leone, Marina Macchini, Diana Giannarelli, Antonio Avallone, Francesca Bruzzese, Eugenia Passaro, Eve Hewitt
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 24(1)
Institutions
Università Cattolica del Sacro Cuore (IT), University of Verona (IT), European Organisation for Rare Diseases (FR), Vita-Salute San Raffaele University (IT), Agostino Gemelli University Polyclinic (IT), Beacon Clinical Research (US), Instituto Ramón y Cajal de Investigación Sanitaria (ES), IRCCS Ospedale San Raffaele (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), European Clinical Research Infrastructure Network (FR), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Funders
European Commission, Ministero della Salute, HORIZON EUROPE Framework Programme